GSK spells out positive Phase 3 data for hepatitis B drug it licensed from Ionis

May 28, 2026 04:30 AM EDTUpdated 06:14 AM R&D GSK's func­tion­al cure da­ta for he­pati­tis B drug are a ma­jor leap over stan­dard of care Ayisha Sharma News Reporter GSK has shared de­tailed re­sults from a pair of late-stage tri­als test­ing a chron­ic he­pati­tis B treat­ment orig­i­nal­ly de­vel­oped by Io­n­is Phar­ma­ceu­ti­cals, with reg­u­la­to­ry re­views … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER